NHS
South West
Genomic Laboratory Hub

SWGLH – Cancer Genomics Test Request Form

Solid Tumour – Adult (non-sarcoma/non-lymphoreticular)

Please complete electronically: type or click in the grey boxes, send this request to the appropriate Histopathology laboratory as soon as possible.

Patient Details: Paste patient demographics here or fill in fields below:

Patient name:		Referring Consultant:
Address: Postcode:		Department and Hospital: Report destination (nhs.net e-mail/s **only**):
DOB:	Gender:	Pathologist:
NHS number:		Date of resection/biopsy:
Pathology block number:		Date sample sent to SW GLH:
Hospital number:		Date of MDT for discussion of result:

Clinical summary:

Genomic tests (please click in the appropriate boxes below to make your selection):

Please refer to the National Genomics Test Directory for Cancer: https://www.england.nhs.uk/publication/national-genomic-test-directories/

Code	Clinical Indication	Test Code	Test Name	Sample Requirements *Refer to key below
M1	Colorectal Carcinoma	M1.1☐	Small variants (KRAS, NRAS, BRAF)	A
		M1.4☐	MSI Testing	A
		M1.5☐	MLH1 promoter hypermethylation	A
M2	Ovarian Carcinoma	M2.1☐	Small variants (BRCA1, BRCA2) ☐1st line ☐2nd line ☐3rd line	A
		M2.4☐	[1]HRD analysis **and** *BRCA1/2* ☐1st line HRD analysis is only available for 1st line patients	10 x 5µm slide mounted sections along with H&E with regions of >20% neoplastic cells highlighted. NB. Curls/Scrolls NOT accepted.
		M2.2☐	Small variants (SMARCA4)	A
M215.2	Endometrial Cancer	M215.2☐	MLH1 promoter hypermethylation	A
M4	Non-Small Cell Lung Cancer	M4.1☐	Small variants (EGFR, BRAF and KRAS)	B
		M4.2☐	ROS1, ALK, RET, NTRK1, NTRK2 and NTRK3 gene fusions	B
		M4.5☐	EGFR hotspot ctDNA	Complete ctDNA referral form
M5	Mesothelioma	M5.1☐	Copy number variant CDKN2A	C
M6	Mucoepidermoid Carcinoma	M6.1☐	Copy number variant MAML2	C
M7	Melanoma - Adult	M7.1☐	Small variants (BRAF, KIT, NRAS)	A
M187	Uveal melanoma	M187.3☐	Small variants (BRAF, NRAS)	A
M8	Gastrointestinal Stromal Tumour	M8.1☐	Small variant (KIT, PDGFRA)	A
M9	Thyroid Papillary Carcinoma - Adult	M9.1☐	Small variants (BRAF, KRAS, NRAS, HRAS)	A
		M9.2☐	RET, NTRK1, NTRK2, NTRK3 gene fusion	A
M10	Thyroid Follicular Carcinoma	M10.1☐	Small variants (KRAS, NRAS, HRAS)	A
M11	Poorly Differentiated Anaplastic Thyroid Carcinoma	M11.1☐	Small variant (TP53)	A
M12	Thyroid Medullary Carcinoma	M12.1☐	Small variants (RET)	A
M13	Phaeochromocytoma	M13.1☐	Small variants (RET)	A
M14	Adrenal Cortical Carcinoma	M14.1☐	Small variants (TP53)	A
M15	Head and Neck Squamous Cell Carcinoma	M15.1☐	Small variants (CDKN2A, EGFR, TP53)	A
		M15.2☐	Structural variants (RET)	A
		M15.4☐	RET, NTRK1, NTRK2, NTRK3 gene fusion	A
M16	Adenoid Cystic Carcinoma	M16.1☐	MYB-NFIB FISH	C
M18	Renal Cell Carcinoma - Adult	M18.1☐	TFE3 rearrangement FISH	C
M220	Cholangiocarcinoma	M220.4☐	FGFR2 fusion analysis	A
M227	Tumour Agnostic	M227.1☐	NTRK fusion analysis	A
	5-Fluorouracil Toxicity		DPYD analysis	Complete Core Form

NHS South West Genomic Laboratory Hub

***Sample Requirements Key:**

A (DNA or RNA extraction only)

☐ Sample with **>20%** neoplastic cells: send one tube (Eppendorf or Universal): containing 5 x 10µm sections (curls/scrolls) OR

☐ Sample with **<20%** neoplastic cells: send 10 x 5µm slide mounted sections along with H&E with regions of >20% neoplastic cells highlighted. NB. If two tests are required the same requirements apply, i.e. it is not necessary to send double the material.

B (DNA and RNA extraction)

☐ Sample with **>20%** neoplastic cells: send two tubes (Eppendorf or Universal): each containing 5 x 10µm sections (curls/scrolls)

☐ Sample with **<20%** neoplastic cells: send 20 x 5µm slide mounted sections along with H&E with regions of >20% neoplastic cells highlighted. NB. If two tests are required the same requirements apply, i.e. it is not necessary to send double the material.

C (FISH)

☐ Please send 2 x 4µm and 2 x 2µm sections on 'APES' or 'sticky' slides **per test** required with an accompanying H&E slide with the appropriate tumour rich area(s) marked.

Any additional information or requests:

Histopathology Report: (please include a copy of the histopathology report for this patient) ☐

Samples should be dispatched as soon as possible as the patient's treatment may be dependent upon the molecular analysis.

Send paperwork and sample to:

Bristol Genetics Laboratory, Pathology Sciences, Southmead Hospital, Bristol BS10 5NB

Phone: 0117 414 6168

Email: nbn-tr.SWGLHcancer@nhs.net

CONSENT STATEMENT It is the referring clinician's responsibility to ensure that the patient/carer knows the purpose of the test and that the DNA sample will be retained in long term storage and may be used for future diagnostic tests. Completing this form is an indication that the clinician has obtained consent for testing and storage. The patient should be advised that the sample may be used anonymously for quality assurance and training purposes. Please advise us of any restrictions.

[1]The HRD testing service is being offered as a Package Deal in accordance with clause 18.1 of the Association of the British Pharmaceutical Industry's Code of Practice. The provision of this service is funded by global co-promotion agreement between AstraZeneca & MSD. The service is delivered in accordance with arrangements agreed with NHS England and NHS Improvement and facilitated by NHS Genomic Laboratory Hubs. The HRD test is performed by Myriad Genetics Inc. in the United States.

[2]FGFR2 fusion testing in cholangiocarcinoma is a service to medicine, funded by Incyte. Testing can be undertaken at any time. However, due to the aggressive nature of the disease it is advised that testing be carried out as early in the patient pathway as possible.